Q3 FY2026 · ended Sep 30, 2026 · Revenue $5.14B, +1.4% YoY · Filed Nov 2, 2026
Boston Scientific Corporation (BSX) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $5.1 billion and net income of $580.0 million. Free cash flow was $868.0 million. As of Sep 30, 2026 it held $609.0 million in cash and investments and $10.9 billion in total debt.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- BSX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Marlborough, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 885725
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
- West Pharmaceutical Services Inc WST
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $5.1B | $5.4B | $5.2B | $5.3B | $5.1B |
| Operating income | $828.0M | $1.2B | $1.1B | $825.0M | $1.0B |
| Net income | $580.0M | $905.0M | $1.3B | $670.0M | $755.0M |
| Diluted EPS | $0.40 | $0.61 | $0.90 | $0.45 | $0.51 |
| Operating cash flow | $1.0B | $1.5B | $348.0M | $1.4B | $1.3B |
| Free cash flow | $868.0M | $1.3B | $171.0M | $1.0B | $1.2B |
| Total assets | $45.5B | $45.2B | $44.4B | $43.7B | $42.7B |
| Stockholders' equity | $25.6B | $24.9B | $25.9B | $24.2B | $23.4B |
| Cash and investments | $609.0M | $539.0M | $1.5B | $2.0B | $1.3B |
| Total debt | $10.9B | $10.9B | $11.0B | $11.7B | $12.0B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 2, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Officer or director change, Other events
|
Oct 7, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 23, 2026 | Sep 21, 2026 |
| 8-K | Current report | Sep 8, 2026 | Sep 7, 2026 |
| 8-K |
Current report
Other events
|
Aug 26, 2026 | Aug 26, 2026 |
All 1001 Boston Scientific Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.